Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

BACKGROUND: To determine the recommended doses of lapatinib (LPT) combined with vinorelbine (VNR) in women with human epidermal growth factor receptor 2-overexpressing advanced breast cancer pretreated with trastuzumab. METHODS: In this phase I study, women were treated with oral daily LPT and i.v....

Descripción completa

Detalles Bibliográficos
Autores principales: Brain, E, Isambert, N, Dalenc, F, Diéras, V, Bonneterre, J, Rezai, K, Jimenez, M, Mefti-Lacheraf, F, Cottura, E, Tresca, P, Vanlemmens, L, Mahier-Aït Oukhatar, C, Lokiec, F, Fumoleau, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322949/
https://www.ncbi.nlm.nih.gov/pubmed/22240778
http://dx.doi.org/10.1038/bjc.2011.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322949/
https://www.ncbi.nlm.nih.gov/pubmed/22240778
http://dx.doi.org/10.1038/bjc.2011.591

Ejemplares similares